Quotient Limited
165 articles about Quotient Limited
-
Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market
12/12/2022
Quotient Limited announced that it has given formal notice to the Nasdaq Stock Market LLC of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market.
-
Quotient Limited Announces Intent to Effect Reverse Stock Split
10/31/2022
Quotient Limited, a commercial-stage diagnostics company, announced that it will effect a one-for-40 reverse stock split of its ordinary shares, nil par value that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market.
-
Quotient Limited Selected to Join the World Economic Forum New Champions Community
9/8/2022
Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced it was selected by the World Economic Forum to join their New Champions Community.
-
Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies
8/24/2022
Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices, headquartered in Amsterdam, the Netherlands has joined MosaiQ Innovator’s Circle.
-
Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th
8/2/2022
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022.
-
Kyowa Kirin announced it is dropping its Parkinson’s disease candidate, KW-6356, a follow-up to Nourianz, despite promising Phase II data that showed the drug is "potentially effective."
-
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu
7/12/2022
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient’s MosaiQ solution.
-
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants
6/29/2022
Quotient Limited announced the closing of its previously announced underwritten public offering of 32,458,336 ordinary shares and pre-funded warrants to purchase 34,208,331 ordinary share for aggregate gross proceeds of approximately $20.0 million.
-
Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update
6/24/2022
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its fourth quarter fiscal 2022 key financial results and provided an update on recent business developments and key upcoming milestones.
-
Quotient Limited Announces Pricing of Underwritten Offering - June 24, 2022
6/24/2022
Quotient Limited announced the pricing of an underwritten public offering of 66,666,667 ordinary shares and ordinary share equivalents for aggregate gross proceeds of $20.0 million.
-
Quotient Limited Announces Proposed Underwritten Offering - June 23, 2022
6/23/2022
Quotient Limited, a commercial-stage diagnostics company, announced the Company intends to commence an underwritten public offering of $20 million of its ordinary shares and, to certain investors in lieu of ordinary shares, pre-funded warrants.
-
Quotient Limited Announces Proposed Amendments to Senior Secured NotesImproved debt terms reduces $93 million principal amortization payments over next 36 months
6/23/2022
Quotient Limited announced that in connection with the public offering announced, the Company has agreed with the beneficial owners of all $132.9 aggregate principal amount of its 12% Senior Secured Notes due 2025 to amend the indenture governing the SSNs to.
-
Quotient Limited Reschedules Fourth Quarter and Full Year 2022 Financial Results Announcement to Friday, June 24th and Provides a Preview of Financials
6/21/2022
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it is rescheduling the release of its financial results for the fourth quarter and full year 2022 ended March 31, 2022.
-
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd
6/17/2022
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2022 will be released before market open on Wednesday, June 22, 2022.
-
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
6/8/2022
Quotient Limited announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner to advance autoimmune diagnostics by leveraging Quotient’s MosaiQ platform.
-
Quotient Limited Announces Opening of Office in Dubai, United Arab Emirates
5/17/2022
Quotient Limited announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion plans to better support customers in the region.
-
Quotient Limited to Host Key Opinion Leader Webinar on its MosaiQ™ Solution
5/12/2022
Quotient Limited, a commercial-stage diagnostics company, announced that it will host a key opinion leader webinar on the current landscape and unmet needs within blood grouping and donor disease screening on Monday, May 23, 2022 at 11:00am ET.
-
Quotient Limited Further Strengthens Scientific and Medical Synergies with the Expansion of the MosaiQ Innovator’s Circle
3/21/2022
Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced New York Blood Center, Inc., USA, and Centro de Transfusiones de la Comunidad de Madrid, Spain have joined MosaiQ’s Innovator’s Circle.
-
Quotient Limited Announces Receipt of CE Mark for the Extended Immunohematology Microarray
3/8/2022
Quotient Limited today announced it has received Conformité Européenne (CE) Mark for its MosaiQ Extended Immunohematology (IH) Microarray.
-
Quotient Limited to Participate in the Cowen 42nd Annual Health Care Conference
2/22/2022
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the Cowen 42nd Annual Health Care Conference.